Peptide Interventions in Dermal and Connective Tissue Health: An Analysis of Melanotan II and Cartalax

This content is sourced exclusively from TruthTides clinical reference data and does not constitute medical advice.

Clinical Question

What is the clinical evidence regarding the efficacy and safety of Melanotan II and Cartalax (Ala-Glu-Asp) for skin health, melanogenesis, and aging-related tissue modulation?

Evidence Snapshot

• Melanotan II

  • Evidence Grade: C
  • Primary Outcome: Confirmed stimulation of melanogenesis (skin darkening).
  • Key Concern: Melanoma promotion concern and non-selective receptor activation.
  • Regulatory Status: Not approved; FDA and TGA safety warnings issued.

• Cartalax (Ala-Glu-Asp)

  • Evidence Grade: C (Low-confidence, borderline C/D).
  • Human Data: One small human study (n=29) embedded in patent documentation; no p-values or Adverse Event (AE) tables provided.
  • Preclinical Data: Rat and MSC models for skin aging, nephroprotection, and chondrocyte proliferation.
  • Regulatory Status: Not FDA/EMA approved; sold as a dietary supplement in Russia.

What the Research Shows

Melanotan II The evidence for Melanotan II confirms its primary intended effect of skin darkening via the stimulation of melanogenesis. Developed originally at the University of Arizona, this compound acts as a non-selective agonist. While tanning is a confirmed outcome, the research highlights significant safety concerns, specifically the potential for melanoma promotion. Because it is non-selective, its clinical utility is complicated by effects beyond the skin, including impacts on appetite and sexual function.

Cartalax (Ala-Glu-Asp) The human evidence for Cartalax in skin and tissue health is limited and categorized as Grade C (low-confidence). The primary clinical data is derived from a single unregistered human study involving 29 patients with knee osteoarthritis, rather than primary dermatological endpoints. In this study, intramuscular dosing (1 µg–5 mg daily for 20 days) resulted in 54.5–62.7% of participants reporting improvements in pain and mobility, though no radiographic improvements were observed.

Regarding skin health specifically, the evidence is currently restricted to preclinical models. Research from the Khavinson group at the St. Petersburg Institute of Bioregulation and Gerontology includes skin aging models and old-rat nephroprotection studies. Preclinical findings indicate that the peptide may influence cell proliferation; for example, rat/MSC chondrocyte proliferation increased by 1.4–2.1x at 200 ng/mL in laboratory settings.

Mechanism

Melanotan II Melanotan II functions as a non-selective melanocortin receptor agonist, targeting receptors MC1R through MC5R. While activation of MC1R stimulates melanogenesis for skin darkening, its non-selective nature leads to the activation of other pathways. Specifically, it activates MC3R and MC4R, which are associated with appetite regulation and sexual function, and MC5R, which is located in the sebaceous glands.

Cartalax (Ala-Glu-Asp) Cartalax is a tripeptide (H-Ala-Glu-Asp-OH) with a molecular weight of 333.29 g/mol. It is proposed to modulate tissue metabolism via the regulation of gene expression. Mechanistic data suggests it influences markers associated with aging and tissue structure, including:

• Chondrocyte Gene Expression: SOX9, aggrecan, type II collagen, and COMP.
• Aging-Related Markers: SIRT1, SIRT6, Ki-67, and p53.

Limitations of the Evidence

Melanotan II The primary limitation of Melanotan II is its non-selective receptor activation, which causes multiple off-target effects. There are significant regulatory barriers, as both the FDA (USA) and TGA (Australia) have issued formal safety communications regarding its use. The potential for melanoma promotion remains a critical evidence gap and safety concern.

Cartalax The evidence for Cartalax is considered high-risk due to the lack of Phase III clinical trials and absence of registered trial data. The human data rests entirely on a difficult-to-audit patent narrative (RU2299741C1 / WO2007139433A1). Reviewers have noted internal dose-rationale inconsistencies within the patent examples. Furthermore, the absence of p-values and adverse event reporting in the human data prevents a robust clinical assessment. If patent-embedded examples are excluded from clinical tiering, the evidence grade would drop to D.

Clinical Takeaway

Melanotan II demonstrates efficacy in skin darkening but is constrained by non-selective receptor activity and significant safety warnings from regulatory bodies. Cartalax shows potential in preclinical aging models and small patent-based human observations, but lacks the rigorous, registered clinical trial data required to confirm efficacy or safety in human skin health. Neither agent is FDA-approved for these indications.

Sources

• TruthTides Database: Melanotan II (Non-selective melanocortin receptor agonist records; FDA/TGA safety communications).
• TruthTides Database: Cartalax (Ala-Glu-Asp; Patent RU2299741C1 / WO2007139433A1 / EA010574B1; Khavinson group research).